5081 Triple combination of 3-weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-positive metastatic breast cancer (MBC): an active and well-tolerated regimen that allows patient compliance

R.Palumbo; A.Bernardo; M.R.Strada; G.Poggi; C.Teragni; A.Amatu; M.Frascaroli; B.Montagna; F.Sottotetti; G.Bernardo

首页> 外文期刊>European Journal of Cancer Supplements >5081 Triple combination of 3-weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-positive metastatic breast cancer (MBC): an active and well-tolerated regimen that allows patient compliance

【24h】

5081 Triple combination of 3-weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-positive metastatic breast cancer (MBC): an active and well-tolerated regimen that allows patient compliance

机译：5081每周3次曲妥珠单抗（T）加上口服长春瑞滨（VNR）和卡培他滨（CAP）的三联组合作为HER2阳性转移性乳腺癌（MBC）的一线治疗：一种有效且耐受性良好的方案，可允许患者依从性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
R.Palumbo; A.Bernardo; M.R.Strada; G.Poggi; C.Teragni; A.Amatu; M.Frascaroli; B.Montagna; F.Sottotetti; G.Bernardo;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. 2124 POSTER Triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer (MBC): latest results of an international phase II trial [J] . A.Chan, V.Ganju, D.Becquart, European Journal of Cancer Supplements . 2007,第4期

机译：2124 POSTER口服长春瑞滨，卡培他滨和曲妥珠单抗的三联组合作为HER2阳性转移性乳腺癌（MBC）的一线治疗：一项国际II期试验的最新结果
2. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. [J] . Arlene Chan, Pier-Franco Conte, Lubos Petruzelka, Anticancer Research: International Journal of Cancer Research and Treatment . 2013,第6期

机译：口服长春瑞滨，卡培他滨和曲妥珠单抗三联疗法作为HER2阳性转移性乳腺癌的一线治疗的II期研究。
3. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. [J] . Arlene Chan, Pier-Franco Conte, Lubos Petruzelka, Anticancer Research: International Journal of Cancer Research and Treatment . 2013,第6期

机译：II型研究口服血红素，Capecitabine和Trastuzumab的三重组合作为HER2阳性转移性乳腺癌中的一线治疗。
4. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
5. Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial [O] . Winston W. Tan, Jacob B. Allred, Muhammad Salim, -1

机译：Capecitabine的II期介入研究（N0337）与血列林和曲妥珠单抗组合的HER2阳性转移性乳腺癌的第一或二线治疗：北中央癌症治疗组试验
6. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results [O] . Edith A. Perez, José Manuel López-Vega, Thierry Petit, 2016

机译：长春瑞滨联合培妥珠单抗和曲妥珠单抗联合治疗HER2阳性局部晚期或转移性乳腺癌患者的一线治疗的安全性和有效性：VELVET研究组1的最终结果

5081 Triple combination of 3-weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-positive metastatic breast cancer (MBC): an active and well-tolerated regimen that allows patient compliance

著录项

相似文献

相关主题

期刊订阅